I think what hasn’t been addressed and to reon’s point is that there needs to be a pathway from where we are today to getting a drug to a $1bn valuation. I don’t think based on today’s announcement or any other announcement previous that there’s any clear sense from the company on the approach, steps or direction needed to be taken to get the drug to a commercial outcome. So there is no way to assess the risk or probability of success right now for this.
Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer, page-25
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
